Skip to content. | Skip to navigation

Personal tools
You are here: Home topics Health Health Guides
Document Actions

Health Guides

Up one level
Guides on the EU Health policy.
The EU and musculoskeletal disorders
Musculoskeletal disorders (MSDs) are the most common work-related health problem in Europe, affecting millions of workers. Across the EU27, 25 per cent of workers complain of backache and 23 per cent report muscular pains. Lighten the load, the European Agency for Safety and Health at Work's 2007 campaign to tackle MSDs in the workplace, supports an integrated management approach with three key elements. First, employers, employees and government need to work together to tackle MSDs. Secondly, any actions should address the ‘whole load on the body’, which covers all the stresses and strains being placed on the body, environmental factors such as cold working conditions, and the load being carried. Thirdly, employers need to manage the retention, rehabilitation and return to work of employees with MSDs.
Organ donation and transplantation in the EU: questions & answers
The European Commission on 30 May 2007 adopted a Communication proposing actions for closer cooperation between Member States in the field of organ donation and transplantation, and announcing plans for a European Directive on quality and safety of organ donation.
Better Training for Safer Food annual report
The Health and Consumer Protection Directorate-General of the European Commission manages the Better Training for Safer Food initiative. This report describes the activity of Better Training for Safer Food in 2006.
Tobacco control in the EU: questions & answers
The majority of European citizens are in favour of smoke-free policies, according to the results of a new Eurobarometer on Tobacco presented by the European Commission to mark World No Tobacco Day on 31 May.
Faster access to better medicines: the Innovative Medicines Initiative
Proposed on 15 May 2007 by the European Commission, the Innovative Medicines Initiative (IMI) seeks to overcome research bottlenecks in the drug development process. Its vision is to create real European leadership in biomedical research and development and thereby reinvigorate the European biopharmaceuticals sector as well as benefiting patients and society in general. IMI will embody a new approach to research financing at the European level, bringing together public and private funds, involving industry, SMEs, and non-profit research institutions. IMI was identified as a candidate Joint Technology Initiative when the EU's 7th Research Framework programme was launched at the beginning of 2007.
Public Health in the EU
In a world where people regularly travel between countries and continents, threats to the health of EU citizens from communicable diseases cannot be quarantined within national borders. Diseases caused by smoking, poor nutrition or pollution are a matter of concern in all EU countries. In the EU single market, the safety of pharmaceuticals or blood products is seen as a shared responsibility. While the primary responsibility for health care lies with EU member states, many public health issues are best dealt with through a concerted EU response.
Food Safety in the European Union
Consumer confidence in the safety of food products has sometimes been shaken in recent years by the cumulative impacts of food-related health crises. Responding to the challenge, the European Union has put in place a comprehensive strategy to restore people's belief in the safety of their food "from the farm to the fork".